RPG Life Sciences completes Actis Generics acquisition
As filed · Update on share purchase agreement dated July 29, 2026, with Actis Generics Private Limited
What happened
FactRPG Active Pharma Limited has completed its acquisition of the entire stake in Actis Generics Private Limited under the share purchase agreement. Effective September 24, 2026, Actis became a subsidiary of RPG Life Sciences and a wholly owned subsidiary of RPG Active Pharma.
Why it matters
CapitSignal interpretationAn acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
DelayedIn Q4 FY26, RPG Life Sciences recorded a 23.6% Y-o-Y increase in revenue, along with a healthy EBITDA margin of 25.6%.
Revenue grew 15.8%, EBITDA by 17.9% and margins by 40 bps y-o-y in Q1 FY27
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Consideration and how it is funded
- Revenue and profit of the target
- Expected completion date
- On the back of continued robust performance, The Board of Directors has recommended highest ever dividend of 2 (management committed by FY25)
- The Board of Directors at its meeting held today has recommended a Final dividend of Rs 24 per equity share i. (management committed by FY26)
Evidence
- Update on share purchase agreement dated July 29, 2026, with Actis Generics Private Limited(opens the original filing in a new tab)
- Earlier statement · Q4 FY26
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- The completion brings Actis Generics into the RPG Life Sciences group, expanding the company’s consolidated subsidiary structure.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%